Trials / Completed
CompletedNCT03214172
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban (Xarelto, BAY59-7939) | 15/20 mg |
Timeline
- Start date
- 2017-07-15
- Primary completion
- 2017-09-15
- Completion
- 2017-09-15
- First posted
- 2017-07-11
- Last updated
- 2018-09-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03214172. Inclusion in this directory is not an endorsement.